Analyst InsightsBiotech StocksStock News Cantor Sees Strong Upside in Catalyst Pharmaceuticals (CPRX) Shares, Sets an $8 Price Target Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. With that in mind, Cantor … Jason Cohen, September 20, 2018
Hedge-Fund NewsStock News Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks Hedge fund manager Mitchell J. Blutt of the $1. Smarter Team, August 30, 2018
Biotech StocksLong IdeasStock News Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company’s flagship candidate … Jason Cohen, August 22, 2018
Biotech StocksInsights Catalyst Pharmaceuticals Inc (CPRX) Shakes Hands with FDA on SPA for Firdapse; SunTrust Chimes In Though NDA Gets Stalled, Analyst Says Catalyst “Still on Track” Joe Rabin, Editor, September 1, 2017
Biotech StocksStock News Stock Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces First Patient Enrolled in Second Phase 3 Trial of Firdapse in LEMS Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced that the first patient has been enrolled into its second Phase 3 clinical trial (designated as LMS-003) to … Corey Williams, December 15, 2016
Biotech StocksStock News Stock Update (NASDAQ:CPRX): Here’s Why Catalyst Pharmaceuticals Inc Shares Are Rising 16% Today Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors have a smile on their faces Thursday morning, after the small biotech company provided an update on its clinical … Corey Williams, December 8, 2016
Biotech StocksStock News Company Update (NASDAQ:CPRX): Here’s Why Catalyst Pharmaceuticals Inc Shares Are Rising 14% Today Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) investors cheer the news that the biopharmaceutical company has reached an agreement with the FDA under a Special Protocol Assessment (SPA) for … Corey Williams, October 31, 2016
Biotech StocksInsights Roth Capital Weighs in on Catalyst Pharmaceuticals Inc (CPRX) Following Meeting with Management Roth Capital analyst Scott Henry is out today with a research note on shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), following recent meeting with the company’s senior management. … Jason Cohen, October 13, 2016
Biotech StocksStock News Company Update (NASDAQ:CPRX): Here’s Why Catalyst Pharmaceuticals Inc Shares Are Up 25% Today Investors in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) are having a great day. Shares of the biotech are up nearly 25% in the wake of analyst upgrade. Corey Williams, October 5, 2016
Biotech StocksStock News Company Update (NASDAQ:CPRX): Catalyst Pharmaceuticals Inc Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the … Corey Williams, September 19, 2016
